MX2019008146A - Virus alterado. - Google Patents

Virus alterado.

Info

Publication number
MX2019008146A
MX2019008146A MX2019008146A MX2019008146A MX2019008146A MX 2019008146 A MX2019008146 A MX 2019008146A MX 2019008146 A MX2019008146 A MX 2019008146A MX 2019008146 A MX2019008146 A MX 2019008146A MX 2019008146 A MX2019008146 A MX 2019008146A
Authority
MX
Mexico
Prior art keywords
altered virus
ctla
virus
altered
antigen
Prior art date
Application number
MX2019008146A
Other languages
English (en)
Spanish (es)
Inventor
Stuart Coffin Robert
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replimune Ltd filed Critical Replimune Ltd
Publication of MX2019008146A publication Critical patent/MX2019008146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2019008146A 2017-01-09 2018-01-09 Virus alterado. MX2019008146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1700350.0A GB201700350D0 (en) 2017-01-09 2017-01-09 Altered virus
PCT/GB2018/050048 WO2018127713A1 (en) 2017-01-09 2018-01-09 Altered virus

Publications (1)

Publication Number Publication Date
MX2019008146A true MX2019008146A (es) 2019-10-09

Family

ID=58463943

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008146A MX2019008146A (es) 2017-01-09 2018-01-09 Virus alterado.
MX2025002735A MX2025002735A (es) 2017-01-09 2019-07-05 Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025002735A MX2025002735A (es) 2017-01-09 2019-07-05 Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer

Country Status (14)

Country Link
US (2) US12059444B2 (enExample)
EP (1) EP3565568B1 (enExample)
JP (2) JP7520511B2 (enExample)
KR (1) KR20190104055A (enExample)
CN (1) CN110198724B (enExample)
AU (1) AU2018205763B2 (enExample)
BR (1) BR112019013215A2 (enExample)
CA (1) CA3049496A1 (enExample)
DK (1) DK3565568T3 (enExample)
ES (1) ES3038026T3 (enExample)
GB (1) GB201700350D0 (enExample)
IL (1) IL267949B2 (enExample)
MX (2) MX2019008146A (enExample)
WO (1) WO2018127713A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3400290T5 (da) 2016-01-08 2024-09-23 Replimune Ltd Onkolytisk virusstamme
EP4089166A1 (en) 2016-01-27 2022-11-16 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP4063859A1 (en) 2017-04-28 2022-09-28 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
CA3071376A1 (en) 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
KR20210135532A (ko) 2019-03-05 2021-11-15 암젠 인크 암 치료를 위한 종양 용해 바이러스의 용도
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
WO2020228828A1 (zh) * 2019-05-15 2020-11-19 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
US20220162644A1 (en) * 2019-05-29 2022-05-26 Orbis Health Solutions, Llc Delivery vectors and particles for expressing chimeric receptors and methods of using the same
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
IL290495A (en) * 2019-08-16 2022-07-01 Immvira Co Ltd Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
WO2024134495A1 (en) * 2022-12-20 2024-06-27 Janssen Biotech, Inc. Oncolytic virus and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
EP0675961B1 (en) 1992-03-31 2002-11-27 Arch Development Corporation Treatment of tumorigenic disease with a modified HSV
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
WO1997012623A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
MXPA02004736A (es) 1999-11-12 2003-01-28 Oncolytics Biotech Inc Virus para el tratamiento de trastornos proliferativos celulares.
KR100802403B1 (ko) 2000-01-21 2008-02-13 바이오벡스 리미티드 바이러스 주
JP4212897B2 (ja) 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
BRPI0515735A2 (pt) 2004-11-04 2011-10-11 Pfizer Prod Inc tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
DK1865986T3 (en) 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
JP2012504959A (ja) 2008-10-08 2012-03-01 イントレキソン コーポレーション 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
AU2010321773A1 (en) 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
EP2619312A1 (en) 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
EP2879498A4 (en) * 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
AU2013308595C1 (en) 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
TR201902073T4 (tr) 2013-09-03 2019-03-21 Medimmune Ltd Bir atenüe Newcastle hastalığı virüsü sağlayan bileşimler ve neoplaziyi tedavi etmek için kullanım yöntemleri.
TR201802728T4 (tr) * 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
US10933106B2 (en) * 2014-02-25 2021-03-02 Deutsches Krebsforschungszentrum RNA viruses for immunovirotherapy
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
JP6895374B2 (ja) * 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP6843736B2 (ja) 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
US20160040186A1 (en) * 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10525557B2 (en) 2015-01-23 2020-01-07 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
DK3400290T5 (da) * 2016-01-08 2024-09-23 Replimune Ltd Onkolytisk virusstamme
EP3380621A4 (en) * 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US20210252135A1 (en) * 2018-06-21 2021-08-19 Replimune Limited Treatment using oncolytic virus

Also Published As

Publication number Publication date
AU2018205763B2 (en) 2025-01-23
ES3038026T3 (en) 2025-10-09
JP2020503871A (ja) 2020-02-06
JP2024095709A (ja) 2024-07-10
US20190343903A1 (en) 2019-11-14
GB201700350D0 (en) 2017-02-22
US12059444B2 (en) 2024-08-13
IL267949B2 (en) 2025-10-01
CN110198724B (zh) 2025-03-18
DK3565568T3 (da) 2025-09-01
CN110198724A (zh) 2019-09-03
BR112019013215A2 (pt) 2019-12-10
US20240358781A1 (en) 2024-10-31
EP4635984A2 (en) 2025-10-22
CA3049496A1 (en) 2018-07-12
MX2025002735A (es) 2025-04-02
KR20190104055A (ko) 2019-09-05
JP7520511B2 (ja) 2024-07-23
IL267949B1 (en) 2025-06-01
EP3565568B1 (en) 2025-08-06
AU2018205763A1 (en) 2019-06-20
EP3565568A1 (en) 2019-11-13
WO2018127713A1 (en) 2018-07-12
IL267949A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2019008146A (es) Virus alterado.
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CY1123358T1 (el) Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CU24568B1 (es) Anticuerpo inhibidor de masp-3
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
CL2019001554S1 (es) Automóvil.
MX2017000985A (es) Anticuerpos anti-pd-1.
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
CO2017005941A2 (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
EA202092435A3 (ru) Моноклональные антитела против bcma
DK3389682T3 (da) Gruppe b-adenovirus, der koder for et anti-tcr-kompleks-antistof eller -fragment
BR112018011089A2 (pt) composições e métodos para a imuno-oncologia
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
MX2016012880A (es) Cadena j modificada.
MX390385B (es) Anticuerpos anti-pd-l1.
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112017027724A2 (pt) terapias de combinação para malignidades hematológicas com anticorpos anti-cd38 e inibidores de survivina
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
CL2019002232S1 (es) Automóvil.
CL2020001201S1 (es) Automóvil.
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
CL2020000174S1 (es) Automóvil.
CU24556B1 (es) Anticuerpos anti-basigin humanizados
CL2018003838S1 (es) Botella.